Prognosia Breast, an AI-driven mammography tool, receives FDA Breakthrough Device status for improved five-year breast cancer risk prediction.
Key Details
- 1FDA granted Breakthrough Device designation to Prognosia Breast, an AI mammography analysis tool.
- 2Developed by Washington University School of Medicine experts.
- 3Tool predicts five-year breast cancer risk from mammogram findings.
- 4Claims to be twice as accurate as current risk assessment methods.
- 5Aims to inform decisions on supplemental imaging and genetic testing.
Why It Matters
FDA's recognition accelerates the path for advanced AI-enabled risk assessment in breast cancer screening. Improved prediction can enhance early intervention and personalisation, potentially reducing morbidity and mortality.
Source
Health Imaging
Related News
•Radiology Business
FDA Clears Multi-Disease AI Screening Platform for CT Imaging
HeartLung Corporation's AI-CVD platform receives FDA clearance to detect multiple diseases from a single CT scan.
•AuntMinnie
AI Projected to Reshape Radiologist Workload But Not Eliminate Jobs
Stanford researchers predict AI could reduce radiologist hours by up to 49% over the next five years, though workforce size is likely to remain stable due to rising imaging demand.
•Cardiovascular Business
FDA Expands Clearance for AI-Guided Echo Exams on Existing Ultrasound Systems
FDA clears UltraSight's AI platform for use with a broader range of existing ultrasound devices, aiding novice users in performing echocardiographic exams.